Phase 1 Diffuse Large B Cell Lymphoma Clinical Trials
22 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 22 trials
Recruiting
Phase 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma+1 more
AstraZeneca227 enrolled27 locationsNCT04594642
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting
Phase 1Phase 2
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHodgkin LymphomaMantle Cell Lymphoma+6 more
New York Medical College20 enrolled1 locationNCT04491370
Recruiting
Phase 1
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaMantle Cell Lymphoma+5 more
British Columbia Cancer Agency24 enrolled7 locationsNCT06208735
Recruiting
Phase 1Phase 2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+8 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 1
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Diffuse Large B Cell LymphomaAcute Lymphoblastic LeukemiaMultiple Myeloma+3 more
Joshua Sasine, MD, PhD20 enrolled1 locationNCT05887167
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+4 more
ModeX Therapeutics, An OPKO Health Company180 enrolled1 locationNCT07249905
Recruiting
Phase 1
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
High-grade B-cell LymphomaDLBCL - Diffuse Large B Cell LymphomaPrimary Mediastinal Large B-cell Lymphoma (PMBCL)+7 more
Poseida Therapeutics, Inc.120 enrolled17 locationsNCT06014762
Recruiting
Phase 1
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
Diffuse Large B Cell LymphomaAcute Lymphoblastic Leukemia
University of Utah10 enrolled1 locationNCT06227026
Recruiting
Phase 1
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting
Phase 1
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+2 more
LTZ Therapeutics, Inc.42 enrolled5 locationsNCT07121946
Recruiting
Phase 1Phase 2
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.90 enrolled25 locationsNCT06829771
Recruiting
Phase 1
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.30 enrolled1 locationNCT07368270
Recruiting
Phase 1
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaMantle Cell Lymphoma+7 more
C. Babis Andreadis36 enrolled1 locationNCT04545762
Recruiting
Phase 1
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Follicular Lymphoma ( FL)Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma Relapsed
GenomeFrontier Therapeutics TW Co., Ltd.18 enrolled1 locationNCT06703892
Recruiting
Phase 1
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
DLBCL - Diffuse Large B Cell Lymphoma
University Health Network, Toronto40 enrolled1 locationNCT05950802
Recruiting
Phase 1
A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B Cell Lymphoma RelapsedEpstein-Barr Virus (EBV) Infection
Thomas Jefferson University30 enrolled1 locationNCT06789159
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Phase 1Phase 2
Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Diffuse Large B Cell LymphomaLarge B-cell LymphomaPrimary Mediastinal Large B Cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd.49 enrolled5 locationsNCT05326243
Recruiting
Phase 1
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaLymphoma, Non-HodgkinFollicular Lymphoma
Weill Medical College of Cornell University38 enrolled1 locationNCT05618366